With 33% CAGR annual value creation since its IPO 20 years ago (over 296 times appreciation*) a study finds that Eurofins ran...
October 24 2017 - 1:30AM
Business Wire
Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (EUFI.PA), the world leader in bioanalytical
testing, celebrates 20 years since the Group’s Initial Public
Offering (IPO) on the 24th of October, 1997. Coinciding with
the anniversary, the UK-based Marten & Co. independent research
firm has published a detailed report examining Eurofins’ value
creation performance over the past 20 years.
Data from Marten & Co.’s research show that in the 20 years
since its IPO, Eurofins ranks highest in terms of its total
returns to shareholders (a TSR of 33.3% compounded annual
growth rate or “CAGR”) among all companies that were listed in
Europe for the whole period, as well as compared to its
publicly-listed peers in both the Testing, Inspection and
Certification and the Healthcare sectors. Investors who have
supported the Group have outperformed key benchmark indices (CAC
40, SBF 120 and S&P 500) by over 29% CAGR on average from
October 1997 to October 2017*.
An investor having invested the equivalent of EUR 3,500 at
Eurofins’ IPO would have over EUR 1 million today including
dividends received.
Eurofins’ value creation track record over the last 20 years
(based on CAGR of total shareholder return) is therefore comparable
to stock market behemoths (Apple 32.5% and Amazon 29.8%). More
importantly, Eurofins’ internal stakeholders have also benefitted
from its success, with over 100 of the Group’s leaders having
accumulated in excess of EUR 1 million capital gains*** from the
Company’s Long Term Incentive (LTI) Stock Program in the
last 20 years and over 200 more than EUR 500,000.
The management of Eurofins believes that beyond the robust
structural drivers supporting its businesses, the Group’s singular
focus on innovation and achieving market leadership in the few
laboratory activities that have a direct positive impact on health
rather than being very diversified has been one of its key success
factors. This strategy has been reflected in significant long-term
investments to ensure that Eurofins has the best laboratory network
with the most state-of-the-art infrastructure and the most
comprehensive analytical service portfolio to serve the food,
environment and pharmaceutical sectors, as well as clinicians and
healthcare providers. It is this relentless commitment to be the
best and most innovative laboratory partner for our clients that
has enabled Eurofins to grow by over 36% per year on average from
EUR 6.6m of revenues in 1997 to EUR 2.5bn in 2016, creating a
cumulative total shareholder return of 29,582% between 24 October
1997 and 10 October 2017.
Comment from Dr. Gilles Martin, Eurofins CEO: “The
inherent value of our activities, both in terms of their positive
impact on health, safety and the environment, and as reflected in
the value we generate for our clients, our employees and all our
stakeholders, drives our passion to continue to build a unique
laboratory infrastructure and deliver the most innovative and best
quality testing service to all our clients. It reinforces our
commitment to remain true to our vision of becoming the world
leader in testing for life, and our mission of contributing
to a safer and healthier world by providing our customers with
innovative and high quality laboratory and advisory services whilst
creating opportunities for our employees and generating
sustainable shareholder value.”
*Based on closing share price of 10th October 2017 – EUR
543.00
**Source: Marten and Co.’s value creation study, 24th October
2017
***Being the sum of pre-tax capital gains realized and potential
gains on outstanding LTI Stock Program at reference share price as
of 10th October 2017.
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 30,000
staff in 400 laboratories across 41 countries, Eurofins offers a
portfolio of over 150,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171023006262/en/
For more information, please visit
www.eurofins.com or contact:Investor
RelationsEurofins Scientific+32 2 766 1620ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Apr 2023 to Apr 2024